Latest Articles
Maipl Therapeutics Advances Non-Hormonal Oral Endometriosis Therapy Targeting Prostaglandin F2α Receptor - Femtech Insider
Maipl Therapeutics Advances Non-Hormonal Oral Endometriosis Therapy Targeting Prostaglandin F2α Receptor Femtech Insider
Published: May 15, 2026, 11:33 a.m.
Hungarian supermodel Barbara Palvin expecting first child with husband Dylan Sprouse - Daily News Hungary
Hungarian supermodel Barbara Palvin expecting first child with husband Dylan Sprouse Daily News Hungary
Published: May 14, 2026, 7:14 p.m.
Former Disney Channel star is expecting first child - Cleveland.com
Former Disney Channel star is expecting first child Cleveland.com
Published: May 14, 2026, 7:01 p.m.
Karyopharm Therapeutics Reports Q1 2026 Results, Advances Selinexor Phase 3 Trials in Myelofibrosis and Endometrial Cancer - Minichart
Karyopharm Therapeutics Reports Q1 2026 Results, Advances Selinexor Phase 3 Trials in Myelofibrosis and Endometrial Cancer Minichart
Published: May 14, 2026, 4:30 p.m.
Maipl Therapeutics Reports Preclinical Progress for MA-4604, a Novel Oral Non-Hormonal Treatment of Endometriosis - Newswise
Maipl Therapeutics Reports Preclinical Progress for MA-4604, a Novel Oral Non-Hormonal Treatment of Endometriosis Newswise
Published: May 14, 2026, 12:40 p.m.
Karyopharm Therapeutics stock (US48576U1060): Q1 revenue beats estimates, trial enrollment complete - AD HOC NEWS
Karyopharm Therapeutics stock (US48576U1060): Q1 revenue beats estimates, trial enrollment complete AD HOC NEWS
Published: May 14, 2026, 12:26 p.m.
Karyopharm completes endometrial cancer trial enrollment - Investing.com
Karyopharm completes endometrial cancer trial enrollment Investing.com
Published: May 14, 2026, 11:52 a.m.
Karyopharm completes endometrial cancer trial enrollment By Investing.com - Investing.com Canada
Karyopharm completes endometrial cancer trial enrollment By Investing.com Investing.com Canada
Published: May 14, 2026, 11:45 a.m.
Karyopharm Therapeut Reports Q1 2026: $35.1M Revenue, $29.2M U.S. Product Sales, Net Loss $22.4M - TradingView
Karyopharm Therapeut Reports Q1 2026: $35.1M Revenue, $29.2M U.S. Product Sales, Net Loss $22.4M TradingView
Published: May 14, 2026, 11:33 a.m.
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment - PR Newswire
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment PR Newswire
Published: May 14, 2026, 11:30 a.m.
Link copied to clipboard!